Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882393 | 0.92 | KIF11 (0.65) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL1893466 | 0.87 | KIF11 (0.56) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL1902045 | 0.86 | KIF11 (0.56) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL1885255 | 0.83 | KIF11 (0.64) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL1883068 | 0.83 | KIF11 (0.51) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL1889094 | 0.82 | KIF11 (0.54) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL1887243 | 0.81 | KIF11 (0.51) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL1890476 | 0.80 | KIF11 (0.66) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL12386697 | 0.80 | KIF11 (0.79) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 | |
| SCHEMBL5756294 | 0.78 | KIF11 (0.70) | KIF11CYP2C19MAP1LC3BCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689724-B1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | NOVARTIS AG (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110190293-A1 | Quinazolinone Compounds as Anticancer Agents | CHIRON CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-20110190293-A1 | Quinazolinone Compounds as Anticancer Agents | CHIRON CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-20110190293-A1 | Quinazolinone Compounds as Anticancer Agents | CHIRON CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-7939539-B2 | Kinesin spindle protein (KSP) inhibitors; 2-substituted 4-(thio)oxo-3,4-dihydroquinazolines; use in combination with other anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939539-B2 | Kinesin spindle protein (KSP) inhibitors; 2-substituted 4-(thio)oxo-3,4-dihydroquinazolines; use in combination with other anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939539-B2 | Kinesin spindle protein (KSP) inhibitors; 2-substituted 4-(thio)oxo-3,4-dihydroquinazolines; use in combination with other anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-1689724-A1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | Chiron Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050209254-A1 | Quinazolinone compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005051922-A1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190293-A1 | Quinazolinone Compounds as Anticancer Agents | TP53, NQO2, TOP1 | KIF11 2740/4885CYP2C19 162/4885MAP1LC3B 1121/4885 |
| US-20050209254-A1 | Quinazolinone compounds as anticancer agents | TP53, NQO2, TOP1 | KIF11 2740/4885CYP2C19 162/4885MAP1LC3B 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.